A Signal S-1 is available at 10k-Wizard, a remnant of their attempt to go public. They've had about $50 million in revenue/equity from their various partners, but don't seem to keep their partners beyond the first dance.
That said, they are playing in a good space, and CELG gets to use its expensive stock.
Here's an extract from their S-1 from February this year:
Our drug discovery engine has enabled us to build a large and diverse portfolio of gene regulating drug targets, drug leads and drug candidates. To date, together with our collaborators, we have:
- advanced drug discovery programs in six major disease areas;
- explored and mapped 10 gene regulating pathways to identify the crucial gene switches that control disease;
- identified 27 drug targets that we believe to be important in disease;
- assembled a screening library of more than 300,000 distinct small molecule compounds and natural products;
- developed 29 drug discovery screens which allow us to search rapidly through our compound library for new drugs;
- identified 24 novel series of potent and selective drug leads that regulate our targets;
- commenced evaluation of drug leads in 15 animal models that mimic human diseases; and
- developed two drug candidates for which we expect to file Investigational New Drug applications, or INDs, in 2000, assuming preclinical studies required to begin human testing are favorably completed without delays.
Our first drug candidate, SP8490, is for treating breast cancer and other cancers. In preclinical animal studies, SP8490, when orally administered, was effective in treating breast cancer and demonstrated equal or superior efficacy to tamoxifen, the current leading hormonal therapy for breast cancer. In addition, SP8490 displayed a superior safety profile in animal models that assess harmful side effects on the uterus. The second drug candidate, NSP6783, is for preventing or treating nerve damage caused by cancer chemotherapy. In animal studies, this orally administered drug candidate provided significant protection of peripheral nerves and their function in an animal model of nerve damage caused by the chemotherapy drug taxol. In these studies, NSP6783 also had a favorable safety profile and did not diminish the anti-cancer effects of the chemotherapeutic drugs taxol or cisplatin. We plan to continue preclinical development for both drug candidates and, assuming favorable completion and no delays in preclinical development, to file INDs by the end of 2000. In addition, we have discovered other gene regulating drug leads that are effective in several animal models, including models of rheumatoid arthritis, asthma and osteoporosis.
We are conducting our drug discovery and development programs both independently and with our corporate collaborators: Nippon Kayaku, Ares-Serono, Axys Pharmaceuticals and DuPont Pharmaceuticals.
Peter |
